University of Mississippi researchers reported a 3D-printed spanlastic drug-delivery approach targeting tumors with localized anticancer dosing. The strategy combines nanotechnology with additive manufacturing to create carriers designed to improve drug delivery at tumor sites. The preclinical concept focuses on addressing precision delivery challenges common in oncology, where systemic exposure can limit therapeutic windows. A printed platform also offers potential scalability advantages versus purely material-synthesis approaches. For the broader field, the study adds to the growing interest in manufacturable, customizable carriers that can be optimized for specific drug-tumor constraints.